ArticleNature communications2026
LysG-driven transcriptional network rewiring underlies lineage-specific phenotypes in Mycobacterium tuberculosis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Mycobacterium tuberculosis complex (MTBC) includes ten human-adapted lineages with varying geography and pathogenicity. Lineage 1 (L1) shows low virulence while Lineage 2 (L2) is hyper-virulent, more transmissible, and associated with drug-resistance. We performed comparative analyses integrating whole-genome sequencing with transcriptomic and proteomic profiling of L1 and L2 clinical strains under two in vitro growth conditions. Transcript-protein correlations varied by strain and gene category, suggesting lineage-specific post-translational regulation. Expression differences scaled with phylogenetic distance, one in three SNPs affected gene expression. A new transcriptional regulatory model identified master transcription factors, linked to the sigma factor network, whose targets were differentially expressed between L1 and L2. For instance, DosR regulon proteins had higher basal levels and exhibited a stronger nitric oxide response in L2. Time-course experiments involving LysG (Rv1985c) induction and wild-type H37Rv under hypoxia and subsequent reaeration confirmed that LysG contributes to reduced metabolic activity, thereby promoting increased tolerance to the novel tuberculosis drug bedaquiline in L2 strains relative to L1. Overall, our findings show how limited genetic variation in the MTBC can yield major phenotypic differences through differential regulation of key transcriptional networks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.